Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424319 | 0.90 | CSF1R (0.43) | MAP2K1SRCCSF1RNUDT1ALDH1A1 | |
| SCHEMBL1343371 | 0.90 | MAP2K1 (0.43) | MAP2K1SRCCLCN2ALDH1A1MAPT | |
| SCHEMBL29413439 | 0.90 | MAP2K1 (0.43) | MAP2K1SRCCLCN2ALDH1A1MAPT | |
| SCHEMBL10305791 | 0.83 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL1488245 | 0.81 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL29413530 | 0.81 | MAP2K1 (0.57) | MAP2K1SRCMAP2K2 | |
| SCHEMBL1488199 | 0.81 | MAP2K1 (0.57) | MAP2K1SRCMAP2K2 | |
| SCHEMBL29413499 | 0.81 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL1343321 | 0.77 | BRAF (0.39) | SRCALDH1A1 | |
| SCHEMBL3973192 | 0.76 | FTO (0.47) | MAP2K1SRCCSF1RCLCN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689233-B1 | BICYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-7772234-B2 | 7-(2,4-Dichlorophenylamino)-8-fluoro-4-methyl-cinnoline-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen activated protein, extracellular signal regulated kinase, kinase inhibitor; cancer and inflammation | ARRAY BIOPHARMA INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1689233-A4 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1689233-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051302-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 33/4885SRC 115/4885CSF1R 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.